It wasn’t just media news that caused supplement companies to begin trying to find hoodia gordonii supplies. Press releases by Phytopharm, a British pharmaceutical company, about researching hoodia and side effects that might be connected with hoodia caused the first stir in the supplement industry.
Phytopharm has two operating divisions; a plant extract division and a pharmaceutical division. In June of 1997, Phytopharm announced that “a naturally occurring appetite suppressant will be resulted in a prescription medicine by Phytopharm “.This is to be Phytopharm’s hoodia gordonii product. News of a naturally occurring appetite suppressant sent, not merely supplement companies, but those who needed to lose excess weight searching because of this “naturally occurring appetite suppressant “.At that time, everyone expected Phytopharm’s hoodia gordonii product to become a prescription drug even though it was consistently described by the company as a “natural anti-obesity treatment “.Their collaboration with Pfizer, another pharmaceutical company, to research hoodia and side effects that may be caused by hoodia use only supported the indisputable fact that Phytopharm’s hoodia gordonii would have been a prescription drug. Now, since they have partnered with Unilever, not a pharmaceutical company, it’s somewhat unclear what Phytopharm’s hoodia gordonii product will be. They do seem focused on the indisputable fact that Phytopharm’s hoodia gordonii will be more advanced than products that are still on the market.
Phytopharm’s product development strategy begins using what they call “evidence of principle” clinical testing. These tests are designed to determine in case a product has got the potential to be safe and effective. Uganda news today Evidence of principle testing of Phytopharm’s hoodia gordonii product began in March of 2001. News about hoodia and side effects were released after this first phase was completed in December of 2001. This is a naturally occurring substance and there were no side effects associated with its use. After completing the first clinical testing, Phytopharm’s strategy advances to the visit a partner company for “late stage development, sales and marketing “.The partner company for Phytopharm’s hoodia gordonii product is Unilever, manufacturers of food products, dietary supplements and over the counter medications. Certainly one of their more famous products is “Slim Fast “.Phytopharm remains researching and investigating the chance or a drug to treat metabolic disorder and hoodia gordonii is the cornerstone because of this drug.
Phytopharm attempts to obtain patents for naturally occurring substances. “Phytopica” is a Phytopharm product for the treating dermatitis in dogs and was just released in April of 2006. Phytopharm’s hoodia gordonii product is patented, but they have had more than a little trouble keeping other manufacturers of natural products from selling their very own hoodia products. In May of 2006, they announced that they were conscious that other individuals were selling hoodia gordonii as a hunger suppressant and that they believed that this might be patent infringement. They stated that they’d contacted the right authorities. The issue is a naturally occurring product can’t be patented. If Phytopharm’s hoodia gordonii product is unique and therefore stronger, safer and better than the hoodia products that are still in the marketplace, then how could there be patent infringement and why would they stress about companies which are selling what they imply are inferior products?
There’s no comparison involving the known side aftereffects of hoodia and side effects connected with appetite suppressants which contain stimulants. Products which contain both hoodia and stimulants could create a problem. It is believed that problems with Ephedra arose as a result to be combined with caffeine or other stimulants. The situation was that this may not be proven without endangering human health. Hopefully, Phytopharm’s hoodia gordonii product will be stimulant free as are many of the hoodia products that are still on the market.